Navigation Links
Inhaled Treprostinil New Drug Application Filed by FDA
Date:9/3/2008

SILVER SPRING, Md., Sept. 3 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary Lung Rx, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for inhaled treprostinil for the treatment of pulmonary arterial hypertension. The NDA will be subject to a standard review period of 10 months, with a targeted user fee deadline of April 30, 2009.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

Lung Rx, Inc. is a biotechnology company focused on unmet medical needs in pulmonary medicine and pulmonary delivery of innovative therapeutic products. [uthr-g]


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
3. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
4. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
5. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
8. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
11. Laser Energetics to Integrate BrightStar(TM) Alexandrite Lasers in Medical and Dental Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 The new Public-Private ... at the association’s recent annual meeting drew praise ... Vice-President Neelie Kroes, who called the action “a huge ... a stimulant to European innovation.” , The Board of ... the new Photonics PPP at its 29 April meeting ...
(Date:5/17/2013)... 17, 2013  Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...
(Date:5/17/2013)...  Insero Health, Inc., a company developing natural compounds ... neurological disorders, is today reporting top-line results from a ... patients with drug-resistant epilepsy.  The data are being presented ... meeting by Dr. Steven Schachter , ... Advisory Board.  In this study, INS001 appeared safe and ...
(Date:5/17/2013)... Frederick, MD (PRWEB) May 17, 2013 ... release of ezColony version 4.1, a versatile refinement ... world-class premier software solution, improves its advanced methodical ... animal facilities with ezColony 4.1. The network-based platform ... to conduct effective research. While continuing to emphasize ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2
... April 27 Cellectricon, a leading,provider of ... announced,its collaboration with BioFocus DPI, a contract ... screening. BioFocus DPI will utilize,Cellectricon,s Dynaflow(R)HT, a ... increase its electrophysiology-based screening capacity, particularly,for fast ...
... SALEM, Mass., April 27 LaVoie Group, a life ... been selected as investor relations agency of record for ... of LaVoie Group, commented, "Pegasus has the opportunity to ... The Company is changing the standard of care ...
... MISSISSAUGA, ON, April 24 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: ... will succeed Terrance H. Gregg as Chairman of its Board ... Gregg,s resignation from Vasogen,s Board is due to the requirements ... , Dr. Smith, a Vasogen Board member since 1998, is ...
Cached Biology Technology:Cellectricon and BioFocus DPI Advance High Throughput ion Channel Drug Discovery 2LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster 2Vasogen Appoints Dr. Eldon Smith Chairman 2Vasogen Appoints Dr. Eldon Smith Chairman 3
(Date:5/17/2013)... proteins in the brain responsible for protecting nerve cells ... increase cell survival. , The discovery, made by researchers ... the EMBO journal with additional comment in ... stroke and other brain diseases. , The research builds ... protein, known as SUMO, responsible for controlling the chemical ...
(Date:5/17/2013)... Dartmouth College study finds human-caused climate change may ... lizards, contradicting a host of recent studies that ... planet. , The findings, which appear in the ... hope for survival of a creature thought to ... that tropical cold-blooded animals, especially forest lizards, will ...
(Date:5/16/2013)... 17, 2013) Illustrating a commitment to the ... Gastroenterological Association (AGA) Research Foundation has announced the ... Fellowship Award recipients. Supported by the National Institute ... this new award helps underrepresented minority students to ... nutrition research. , "By establishing this new award, ...
Breaking Biology News(10 mins):SUMO wrestling cells reveal new protective mechanism target for stroke 2Climate change may have little impact on tropical lizards 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
... 18, 2007)Researchers at The University of Texas Medical School ... glucose metabolism and spina bifida. The decade-long study looked ... their children with that birth defect. UT Medical ... take part in glucose metabolism to look for a ...
... 400 grizzly bears are stored at Montana State University, waiting ... Ecosystem. Ranging from pale blond to almost black, the ... is minus-77.8 degrees. Some of the tufts are almost 25 ... a few months to be analyzed at Wildlife Genetics International ...
... Developing fetuses are extremely sensitive to radiation, which ... of screening or treatment for cancer. Now researchers from ... modeling tools that could enable safer, more accurate, and ... for pregnant women. Radiation is a doubled-edged sword: ...
Cached Biology News:UT-Houston's Northrup and colleagues uncover genetic link to spina bifida 2Study of bear hair will reveal genetic diversity of Yellowstone's grizzlies 2Safer, more accurate radiation therapy for expecting mothers 2Safer, more accurate radiation therapy for expecting mothers 3
XEDAR Antibody...
Pharmalyte, narrow range pH 4.2-4.9, 25 ml. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Immobiline for IEF and Carrier Ampholytes....
...
...
Biology Products: